BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34387990)

  • 1. Machine Learning Models Identify Inhibitors of SARS-CoV-2.
    Gawriljuk VO; Zin PPK; Puhl AC; Zorn KM; Foil DH; Lane TR; Hurst B; Tavella TA; Costa FTM; Lakshmanane P; Bernatchez J; Godoy AS; Oliva G; Siqueira-Neto JL; Madrid PB; Ekins S
    J Chem Inf Model; 2021 Sep; 61(9):4224-4235. PubMed ID: 34387990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
    Kadioglu O; Saeed M; Greten HJ; Efferth T
    Comput Biol Med; 2021 Jun; 133():104359. PubMed ID: 33845270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico Identification of Anti-SARS-CoV-2 Medicinal Plants Using Cheminformatics and Machine Learning.
    Liang J; Zheng Y; Tong X; Yang N; Dai S
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning prediction of 3CL
    Bucinsky L; Bortňák D; Gall M; Matúška J; Milata V; Pitoňák M; Štekláč M; Végh D; Zajaček D
    Comput Biol Chem; 2022 Jun; 98():107656. PubMed ID: 35288359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SperoPredictor: An Integrated Machine Learning and Molecular Docking-Based Drug Repurposing Framework With Use Case of COVID-19.
    Ahmed F; Lee JW; Samantasinghar A; Kim YS; Kim KH; Kang IS; Memon FH; Lim JH; Choi KH
    Front Public Health; 2022; 10():902123. PubMed ID: 35784208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset.
    García R; Hussain A; Koduru P; Atis M; Wilson K; Park JY; Toby I; Diwa K; Vu L; Ho S; Adnan F; Nguyen A; Cox A; Kirtek T; García P; Li Y; Jones H; Shi G; Green A; Rosenbaum D
    Comput Biol Med; 2021 Jun; 133():104364. PubMed ID: 33895457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning-based integration of network features and chemical structure of compounds for SARS-CoV-2 drug effect analysis.
    Späth J; Wang RS; Humphrey M; Baumbach J; Loscalzo J
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):257-269. PubMed ID: 37950385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation.
    Nayarisseri A; Khandelwal R; Madhavi M; Selvaraj C; Panwar U; Sharma K; Hussain T; Singh SK
    Curr Top Med Chem; 2020; 20(24):2146-2167. PubMed ID: 32621718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
    Amin SA; Ghosh K; Gayen S; Jha T
    J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.
    Williams AH; Zhan CG
    BioDrugs; 2023 Sep; 37(5):649-674. PubMed ID: 37464099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning-driven blood transcriptome-based discovery of SARS-CoV-2 specific severity biomarkers.
    Krishnamoorthy P; Raj AS; Kumar H
    J Med Virol; 2023 Feb; 95(2):e28488. PubMed ID: 36625381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.